Tufton Capital Management lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.7% during the fourth quarter, Holdings Channel reports. The fund owned 85,429 shares of the company’s stock after selling 623 shares during the period. Johnson & Johnson makes up approximately 2.3% of Tufton Capital Management’s holdings, making the stock its 7th biggest holding. Tufton Capital Management’s holdings in Johnson & Johnson were worth $11,936,000 at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. Harding Loevner LP bought a new position in shares of Johnson & Johnson in the 2nd quarter valued at about $106,000. Mountain Capital Investment Advisors Inc bought a new position in shares of Johnson & Johnson in the 2nd quarter valued at about $124,000. Cerebellum GP LLC bought a new position in shares of Johnson & Johnson in the 4th quarter valued at about $166,000. Lenox Wealth Management Inc. boosted its stake in shares of Johnson & Johnson by 1.7% in the 2nd quarter. Lenox Wealth Management Inc. now owns 1,457 shares of the company’s stock valued at $193,000 after purchasing an additional 24 shares during the last quarter. Finally, Jentner Corp bought a new position in shares of Johnson & Johnson in the 4th quarter valued at about $209,000. 67.23% of the stock is currently owned by hedge funds and other institutional investors.
Shares of JNJ stock opened at $126.66 on Friday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.12 and a current ratio of 1.41. The company has a market cap of $342,660.25, a price-to-earnings ratio of 17.35, a P/E/G ratio of 2.03 and a beta of 0.74. Johnson & Johnson has a 52 week low of $121.54 and a 52 week high of $148.32.
Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 17th. The company reported $2.06 EPS for the quarter, topping the consensus estimate of $2.00 by $0.06. The firm had revenue of $20.01 billion for the quarter, compared to the consensus estimate of $19.50 billion. Johnson & Johnson had a net margin of 1.58% and a return on equity of 30.05%. The business’s quarterly revenue was up 12.6% on a year-over-year basis. During the same period last year, the company posted $1.83 EPS. analysts forecast that Johnson & Johnson will post 8.12 EPS for the current year.
In other Johnson & Johnson news, VP Paulus Stoffels sold 155,342 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the sale, the vice president now directly owns 357,906 shares in the company, valued at approximately $46,477,673.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.22% of the company’s stock.
JNJ has been the topic of several recent research reports. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $146.00 target price on the stock in a research note on Thursday, April 5th. Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $152.28 target price on the stock in a research note on Tuesday, January 23rd. Stifel Nicolaus raised their target price on shares of Johnson & Johnson from $142.00 to $145.00 and gave the company a “hold” rating in a research note on Wednesday, January 24th. Credit Suisse Group set a $154.00 price target on shares of Johnson & Johnson and gave the company a “hold” rating in a research report on Monday, January 22nd. Finally, Morgan Stanley cut their price target on shares of Johnson & Johnson from $148.00 to $143.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 10th. Five research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have issued a buy rating to the company’s stock. Johnson & Johnson presently has an average rating of “Hold” and a consensus target price of $142.83.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/21/johnson-johnson-jnj-holdings-reduced-by-tufton-capital-management.html.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.